Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

57.69 +0.19 (+0.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,520,628
Open 58.59
Bid (Size) 55.50 (100)
Ask (Size) 60.46 (100)
Prev. Close 57.50
Today's Range 57.18 - 59.78
52wk Range 38.51 - 85.25
Shares Outstanding 42,600,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline ↗
Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company... 
Via MarketBeat

Performance

YTD
-28.6%
-28.6%
1 Month
-5.1%
-5.1%
3 Month
-14.8%
-14.8%
6 Month
-21.7%
-21.7%
1 Year
+38.8%
+38.8%

More News

Read More
News headline image
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme ↗
Via Benzinga
Topics Law Enforcement
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips ↗
Via Chartmill
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen ↗
Via Chartmill
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Q4 2025 Earnings: Revenue Soars on XDEMVY Sales, But Losses Widen ↗
Via Chartmill
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus (TARS) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
Via The Motley Fool
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus (TARS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Tarsus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Tarsus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Tarsus Pharmaceuticals, Inc. - Common Stock trade on?
Tarsus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock is TARS on the Nasdaq Stock Market
What is the current price of Tarsus Pharmaceuticals, Inc. - Common Stock?
The current price of Tarsus Pharmaceuticals, Inc. - Common Stock is 57.69
When was Tarsus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Tarsus Pharmaceuticals, Inc. - Common Stock was at 07/16/26 04:00 PM ET
What is the market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock is 2.46B
How many shares of Tarsus Pharmaceuticals, Inc. - Common Stock are outstanding?
Tarsus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.